Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 3Multiple Myeloma 2Recurrence 1Ovarian Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × lorvotuzumab mertansine × Clear all
NCT01237678 2018-01-18

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Terminated
181 enrolled 17 charts
Thoracic

Small Cell Lung Carcinoma

NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ImmunoGen, Inc.

Phase 1 Completed
97 enrolled
DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT00065429 2012-07-18

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Completed
64 enrolled 13 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡